Inovio Pharmaceuticals, Inc. (INO)

0,9137 -0,0488 (-5,07%) Al cierre: 04:00PM EDT

Inovio Pharmaceuticals, Inc.

660 West Germantown Pike
Suite 110
Plymouth Meeting, PA 19462
United States
267 440 4200
https://www.inovio.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 184

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Jacqueline E. Shea Ph.D.	CEO, Pres & Director	698,85k	908,99k	1966
Mr. Peter D. Kies	Chief Financial Officer	686,51k	271,76k	1963
Dr. Laurent M. Humeau Ph.D.	Chief Scientific Officer	672,26k	N/A	1967
Ben Matone	Director of Investor Relations	N/A	N/A	N/A
Mr. Robert L. Crotty J.D.	Gen. Counsel	N/A	N/A	1974
Ms. Asli Gevgilili	Chief HR Officer	N/A	N/A	N/A
Mr. E. J. Brandreth MBA	Sr. VP of Quality Assurance	N/A	N/A	N/A
Dr. Jeffrey Skolnik	Sr. VP of Clinical Devel.	N/A	N/A	N/A
Mr. Robert J. Juba Jr.	Sr. VP of Biological Manufacturing & Clinical Supply Management	N/A	N/A	N/A
Mr. Daniel Jordan	Sr. VP of Device Manufacturing Operations	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2021 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia, including cervical, vulvar, and anal dysplasia and is under phase II/III clinical trials; INO-3107 for HPV-related recurrent respiratory rapillomatosis and is under Phase 1/2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under phase 1b trial; and INO-4500 vaccine for lassa fever, which is under phase 1b trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Gobierno corporativo

El ISS Governance QualityScore de Inovio Pharmaceuticals, Inc., a día 1 de marzo de 2023, es 5. Las puntuaciones base son Auditoría: 8; Tablero: 2; Derechos de los accionistas: 4; Compensación: 8.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.